Available Forms: Tablets
Available Strengths: 200mg
Reference Brands: COMTAN (USA/EU), ENTACOM (EU), ENTALIN (EU)
Category: Neurology
Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), an enzyme involved in dopamine breakdown. It is used as an adjunct to levodopa/carbidopa therapy in patients with Parkinson’s disease to prolong the effect of levodopa and improve motor control. The medicine is taken orally, usually with each levodopa dose. Its common brand name is Comtan, available as 200 mg film-coated tablets worldwide.
Quick Response Guaranteed | Verified Suppliers
Entacapone is used in the treatment of Parkinson’s disease. It is given along with levodopa and carbidopa to help improve and prolong the effects of levodopa by preventing its breakdown in the body. This helps reduce symptoms such as stiffness, tremors, and movement difficulties in patients with Parkinson’s disease.
Entacapone is made from Entacapone, a selective and reversible inhibitor of the enzyme catechol-O-methyltransferase (COMT), which helps increase and maintain dopamine levels in the brain.
The common trade names of Entacapone include Comtan and Stalevo (a combination of carbidopa, levodopa, and entacapone).
Entacapone (Comtan) is manufactured by Novartis Pharmaceuticals and marketed globally by Orion Corporation and other licensed companies.
The generic name of Entacapone is Entacapone.
The brand names of Entacapone are Comtan and Stalevo.
Entacapone is manufactured in Finland by Orion Corporation and in several other countries under license by Novartis and approved pharmaceutical manufacturers.
Strength: 125 mg/mL, 200 mg, 250 mg, 300 mg, 500 mg, 100 mg/mL
Form: Tablet / Capsule/ Injection / Oral syrup
Reference Brands: Depakene (USA), Depakine (EU/LATAM), Valprol (India)
Strength: 50 mg, 100 mg
Form: Tablets
Reference Brands: Ubrelvy (USA/India)
Strength: 100 mg
Reference Brands: Tasmar (USA/EU)
Strength: 50 mg ,100 mg
Reference Brands: Xadago (USA/EU)
By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under ‘Fair use.’
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Stay updated on pharma trends and marketplace opportunities.
Online · B2B Pharma · Medical Tourism · NPP